(A) To be acceptable to the board, a course of study shall meet the following requirements:
(1) Be a minimum of forty-five contact hours in length and include content which ensures sufficient preparation for the safe and effective prescribing of drugs and therapeutic devices;
(2) Include content which is specific to the participant’s nursing specialty and which includes all of the following:
(a) A minimum of thirty-six hours of training, obtained from a single provider, in:
(i) Pharmacokinetic principles and clinical application; and
(ii) Principles of the use of drugs and therapeutic devices in the prevention of illness and maintenance of health;
(b) A combined six hours of training consistent with divisions (B)(3)(b) and (B)(3)(c) of section 4723.482 of the Revised Code.
(3) Include a process for interaction of the participants with instructional personnel;
(4) Include a process for evaluating the participants’ learning of the content required by this rule that includes:
(a) Successful completion of case studies or written assignments;
(b) Successful completion of a comprehensive written examination; and
(c) A mechanism to assure the security of the evaluation process;
(5) Be faculty-directed and obtained either from:
(a) An accredited educational institution acceptable to the board; or
(b) A continuing education program in pharmacology that has been approved by a board approver according toChapter 4723-14 of the Administrative Code.
Effective: 02/01/2011
R.C. 119.032 review dates: 10/08/2010 and 10/01/2015
Promulgated Under: 119.03
Statutory Authority: 4723.50
Rule Amplifies: 4723.482
Prior Effective Dates: 10/01/2001, 02/01/2002, 02/01/2003, 04/01/2006